This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 Sep;14(10):e387-8.

doi: 10.1016/S1470-2045(13)70297-3.

The ZOOM trial: more boon than doom?

Brian Hutton, Christina L Addison, Mark Clemons

PMID: 23993380
DOI: 10.1016/S1470-2045(13)70297-3

Comment

The ZOOM trial: more boon than doom?

Brian Hutton et al. Lancet Oncol. 2013 Sep.

. 2013 Sep;14(10):e387-8.

doi: 10.1016/S1470-2045(13)70297-3.

Authors

Brian Hutton, Christina L Addison, Mark Clemons

PMID: 23993380
DOI: 10.1016/S1470-2045(13)70297-3

No abstract available

PubMed Disclaimer

Comment on

Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.
Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI. Amadori D, et al. Lancet Oncol. 2013 Jun;14(7):663-70. doi: 10.1016/S1470-2045(13)70174-8. Epub 2013 May 16. Lancet Oncol. 2013. PMID: 23684411 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information